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Abstract
Background: Pancreatic cancer (PaCa) is a fatal human cancer due to its exceptional resistance
to all current anticancer therapies. The cytoprotective enzyme heme oxygenase-1 (HO-1) is
significantly overexpressed in PaCa and seems to play an important role in cancer resistance to
anticancer treatment. The inhibition of HO-1 sensitized PaCa cells to chemo- and radiotherapy in
vitro.
Therefore, we investigated the effects of HO-1 and its metabolites biliverdin, carbon monoxide and
iron on PaCa cells.
PaCa cell lines with divergent HO-1 expression patterns were used in a murine orthotopic cancer
model. HO-1 expression and activity was regulated by zinc (inhibition) and cobalt (induction)
protoporphyrin. Furthermore, the influence of cellular HO-1 levels and its metabolites on effects
of standard chemotherapy with gemcitabine was tested in vivo and in vitro.
Results: High HO-1 expression in PaCa cell lines was associated with increased chemoresistance
in vitro. Chemoresistance to gemcitabine was increased during HO-1 induction in PaCa cells
expressing low levels of HO-1. The inhibition of HO-1 activity in pancreatic tumors with high HO-
1 boosted chemotherapeutic effects in vivo significantly. Furthermore, biliverdin and iron promoted
PaCa resistance to chemotherapy. Consequently, specific iron chelation by desferrioxamine
revealed profound anticancerous effects.
Conclusion: In summary, the inhibition of HO-1 and the chelation of iron in PaCa cells were
associated with increased sensitivity and susceptibility of pancreatic tumors to chemotherapy in
vivo. The metabolites biliverdin and iron seem to be involved in HO-1-mediated resistance to
anticancer treatment. Therefore, HO-1 inhibition or direct interference with its metabolites may
evolve new PaCa treatment strategies.
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Background
Pancreatic cancer is one of the most serious human can-
cers with an incidence rate that almost equals its mortality
rate [1]. Most patients show advanced unresectable
tumors at the time of diagnosis. Despite efforts in the last
decades, surgical resection of the tumor is still the only
approach for potential cure, as PaCa is nearly insensitive
to standard radiation and chemotherapeutic treatments
[2].
Heme oxygenase-1 (HO-1) is the inducible isoform of the
three heme oxygenases (HO-1, HO-2 and HO-3) that cat-
alyze the degradation of heme to biliverdin, carbon mon-
oxide (CO) and free iron [3]. Subsequently, the cytosolic
enzyme biliverdin reductase converts biliverdin into
bilirubin. Free iron is promptly sequestered by ferritin
[4,5].
HO-1 and its products possess anti-inflammatory and
anti-apoptotic properties [6-8]. Furthermore, HO-1 regu-
lates cell proliferation [9] and functions as an important
proangiogenic mediator [10-12].
Elevated HO-1 expression and activity were observed in
various tumor tissues such as human renal cell carcinoma
[13], prostate tumors [14], lymphosarcomas [15] and
PaCa [16]. In response to radio- and chemotherapy, HO-
1 expression is potently increased [16,17]. Therefore, it
was hypothesized that HO-1 and its products may have
important roles in tumor progression and formation of
metastases as well as resistance to anticancer therapy. It
was shown that the antioxidative and antiapoptotic prop-
erties of HO-1 are related to these effects [12,18]. In an
experimental murine PaCa model, HO-1 accelerated
tumor growth by increasing angiogenesis [10]. Further-
more, human PaCa tissues showed increased expression
of HO-1 in tumor cells and in tumor associated immuno-
cytes. Targeted knockdown of HO-1 gene expression in
vitro was associated with growth inhibition of PaCa cells
and increased chemo- and radiosensitivity of tumor cells
significantly [16].
In this study we tested potential anticancerous effects of
HO-1-inhibition in vivo and therefore aimed for a poten-
tial therapeutic approach for sensitizing tumors to chem-
otherapy. Furthermore, the role of HO-1 metabolites in
this context should be analyzed.
Results
Pancreatic cancer cell lines PANC-1 and S2-013 show 
divergent HO-1 expression levels
To confirm expression of HO-1 in the present cell lines
and to check the effect of gemcitabine treatment, mRNA-
and protein levels were examined using RT-PCR and West-
ern blot analysis. Cell lines showed divergent mRNA-
expression levels of HO-1 (Fig. 1A). Native expression was
high in PANC-1 (1063.33 ± 43.10 copies/μl cDNA),
whereas S2-013 (153.67 ± 24.54 copies/μl cDNA) indi-
cated low levels of HO-1 expression. HO-1 mRNA expres-
sion was induced in PANC-1 cancer cells treated with
gemcitabine.
Protein analyses revealed high native expression of HO-1
in PANC-1 in comparison to S2-013 cell line, which
showed only faint expression. Under gemcitabine condi-
tions protein expression of HO-1 was slightly induced in
PANC-1 cell line but did not alter in S2-013 cell line (Fig.
1B).
Different HO-1 expression levels are associated with 
variable susceptibility to chemotherapy
Both cell lines revealed profound growth inhibition under
treatment with gemcitabine (Fig. 2). PANC-1 cell line
(LD50 [PANC-1] ~7.53 ng/ml) with high native HO-1
expression showed significantly greater chemoresistance
than S2-013 cell line (LD50 [S2-013] ~2.13 ng/ml) with
low native HO-1 expression.
Inhibition of HO-1 activity leads to increased susceptibility 
to chemotherapy in vitro
To prove cytoprotective properties of HO-1 to anticancer
treatment, the HO-1 inductor CoPP and ZnPP, which has
been shown to inhibit HO-1 activity in vitro and in vivo
[7,19-21], were added to tumor cells 24 h prior to the
application of gemcitabine.
In the PANC-1 cell line, application of ZnPP under gem-
citabine treatment revealed a dose dependent growth
inhibition (-43.30 ± 5.89%), whereas application of CoPP
had no significant effect on cell proliferation (-9.99 ±
8.31%) (Fig. 3A). In the S2-013 cell line implementation
of CoPP increased cell proliferation (+15.49 ± 10.88%),
whereas ZnPP had no significant effect (+0.11 ± 5.93%)
(Fig. 3B).
The cell lines S2-013 and PANC-1 were utilized for ortho-
topic tumor cell injection in nude mice, as previously
described for S2-013 cells [22].
Mice receiving PANC-1 cancer cells treated with gemcitab-
ine showed significantly reduced tumor growth in com-
parison to untreated control (-43.61 ± 15.12%) (Fig. 4A).
Inhibition of HO-1 activity by ZnPP boosted anticancer-
ous effects of gemcitabine resulting in significant reduc-
tion of tumor growth in gemcitabine treated mice with
PANC-1 tumors (-59.26 ± 15.32%) (P < 0.05) as opposedMolecular Cancer 2009, 8:37 http://www.molecular-cancer.com/content/8/1/37
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to gemcitabine treated tumors only (-43.61 ± 15.12%).
Administration of CoPP in combination with gemcitab-
ine tended to increased tumor weights in comparison to
gemcitbine treatment only.
In S2-013 cell line, administration of CoPP in combina-
tion with gemcitabine facilitated pancreatic tumor pro-
gression tending to result in higher tumor weights in
comparison to gemcitabine alone. The use of ZnPP in
combination with gemcitabine tended to result in lower
tumor growth (Fig. 4B) but was not significantly different.
HO-1 metabolites make pancreatic cancer cells more 
resistant to chemotherapy
To study possible effects of HO-1 metabolites biliverdin,
CO and free iron on growth behavior of PaCa cell lines
further proliferation experiments were performed.
Application of biliverdin [5 and 50 μmol/l] resulted in
increased cell proliferation for PANC-1 (+106.43 ±
27.68%) and S2-013 (+62.45 ± 42.67%) cancer cells (Fig.
5A).  In vivo, implementation of biliverdin tended to
increase tumor growth (S2-013) in gemcitabine treated
mice (data not shown).
Ferrous histidinate was used to study the effects of the
HO-1 metabolite iron. Administration of ferrous histidi-
Pancreatic cancer cell lines PANC-1 and S2-013 show diver- gent HO-1 expression levels Figure 1
Pancreatic cancer cell lines PANC-1 and S2-013 show 
divergent HO-1 expression levels. mRNA extractions 
from cells for QRT-PCR and cell lysates for Western blot 
were prepared from untreated cells and cells treated with 
gemcitabine. (1A) No treatment of PANC-1 cells displayed 
high native mRNA expression of HO-1, whereas HO-1 
expression was only at levels of detection in S2-013. Treat-
ment with gemcitabine increased mRNA expression of HO-1 
in PANC-1 cells but did not alter the expression level in S2-
013 cancer cells. (1B) Protein analyses in resting condition 
revealed high native expression of HO-1 in PANC-1 but faint 
expression in S2-013. Under gemcitabine conditions protein 
expression of HO-1 was slightly induced in PANC-1 cell line 
but did not alter HO-1 protein expression in S2-013 cell line.
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Different HO-1 expression levels are associated with variable  susceptibility to chemotherapy Figure 2
Different HO-1 expression levels are associated with 
variable susceptibility to chemotherapy. Cell viability 
was assessed 72 h after application of gemcitabine via MTT 
assay. Both cell lines showed dose dependent growth inhibi-
tion under treatment with gemcitabine. S2-013 cell line with 
low native HO-1 expression was significantly more suscepti-
ble to gemcitabine (LD50 [S2-013] ~2.13 ng/ml) than PANC-
1 cell line with high native HO-1 expression (LD50 [PANC-
1] ~7.53 ng/ml).
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nate in high concentrations increased the proliferation of
PANC-1(+32.45 ± 15.80%) and S2-013 (+53.63 ± 0.77%)
cancer cells (Fig. 5B). CO exposure to PANC-1 and S2-013
showed a nonsignificant tendency towards increased can-
cer cell growth (data not shown).
Depletion of iron increases susceptibility to chemotherapy 
in vivo and in vitro
The use of DFO resulted in significantly reduced cell pro-
liferation in PANC-1 (-50.91 ± 15.93%) and S2-013 (-
35.26 ± 4.64%) cell lines in vitro (Fig. 6A). Furthermore,
administration of DFO was associated with a significantly
lower tumor growth in vivo in mice implanted S2-013 cell
line when combined with gemcitabine (-51.13 ± 14.66%)
(Fig. 6B).
Discussion
The HO-1 system has important cellular functions in self-
defense processes resisting a wide range of external stress
stimuli and in growth regulation [9,23]. In experimental
and clinical approaches for various HO-1 associated dis-
orders [24,25], HO-1 and its metabolites with their anti-
inflammatory and anti-apoptotic properties provide pro-
tection for cells, tissues and even whole organs. Further-
more, HO-1 inducers influence certain diseases in
particular [9]. In transgenic mice, cardiac-specific expres-
Inhibition of HO-1 activity leads to increased susceptibility to  chemotherapy in vitro Figure 3
Inhibition of HO-1 activity leads to increased suscep-
tibility to chemotherapy in vitro. Cell viability was 
assessed 72 h after application of gemcitabine via MTT assay. 
(3A) Under gemcitabine treatment (LD50 dose) application 
of ZnPP revealed a dose dependent growth inhibition of 
PANC-1 cancer cells, whereas application of CoPP had no 
significant effect on cell proliferation. (3B) In S2-013 cell line 
implementation of CoPP led to increased cell proliferation, 
whereas ZnPP had no significant effect.
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Inhibition of HO-1 activity leads to increased susceptibility to  chemotherapy of solid tumor growth Figure 4
Inhibition of HO-1 activity leads to increased suscep-
tibility to chemotherapy of solid tumor growth. Pri-
mary pancreatic tumor weights were assessed 4 and 8 weeks 
after orthotopic tumor implantation of cancer cells in nude 
mice (n = 60, 15 per group). (4A) ZnPP treatment reduced 
tumor growth in gemcitabine treated mice after PANC-1 
cancer cell implantation significantly, compared to gemcitab-
ine treated tumors only. (4B) Administration of gemcitabine 
in combination with CoPP or ZnPP in mice implanted S2-013 
cancer cells did not significantly change tumor weights in 
comparison to gemcitabine treatment alone. The use of 
ZnPP in combination with gemcitabine showed a trend 
towards lower tumor growth.
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sion of HO-1 offered protection against ischemia and
reperfusion injury [26]. Exogenous administration of HO-
1 by gene transfer provided protection against hyperoxia
induced lung injury in rats [27].
HO-1 is highly upregulated in different human cancers
including pancreatic carcinoma [5,13,14,16]. It has been
shown that inhibition of HO-1 expression and activity by
siRNA transfection in different PaCa cell lines diminished
cell proliferation and enhanced their response to HO-1-
inducing radiation and chemotherapeutics [16]. In an
experimental mouse model, HO-1 accelerated angiogen-
esis in human PaCa [10]. HO-1 expression in cancer cells
surrounding immunocytes [16] could be associated with
promoted local tumor growth as expression of HO-1 in
macrophages is correlated with neovascularization
[28,29].
Thus, overexpression of HO-1 in PaCa may develop
tumor-promoting activity by enhancing cell proliferation,
improving resistance to oxidative stress and apoptotic
stimuli and increasing angiogenic potential of tumor cells.
The present study demonstrated that high expression lev-
els of native HO-1 were associated with impaired suscep-
tibility to chemotherapy in PaCa cell lines. Furthermore,
we confirmed the antiproliferative and sensitizing effect
of HO-1 inhibition on PaCa cells in vitro. Treatment with
HO-1 activity inhibitor ZnPP, in addition to gemcitabine,
reduced cell proliferation in PANC-1 expressing high lev-
els of native HO-1.
Moreover, we show that the inhibition of HO-1 activity in
vivo significantly increased the susceptibility to chemo-
HO-1 metabolites mediate resistance effects to chemother- apy Figure 5
HO-1 metabolites mediate resistance effects to 
chemotherapy. Cell growth was assessed 72 h after appli-
cation of gemcitabine via MTT assay. (5A) Biliverdin adminis-
tration biliverdin [5 and 50 μmol/l] resulted in increased 
proliferation of cancer cell line PANC-1 and S2-013, and 
therefore reduced the chemotherapeutic effect of gemcitab-
ine (LD50 dose). (5B) Administration of ferrous histidinate 
revealed increased cell proliferation of PANC-1 and S2-013 
cancer cells.
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Depletion of iron increases susceptibility to chemotherapy in  vivo and in vitro Figure 6
Depletion of iron increases susceptibility to chemo-
therapy in vivo and in vitro. Cell growth was assessed 72 h 
after application of gemcitabine via MTT assay. (6A) Imple-
mentation of DFO resulted in dose dependent profound 
growth inhibition of both cell lines. (6B) Primary pancreatic 
tumor weights were assessed 4 weeks after orthotopic 
tumor implantation of S2-013 cancer cells in nude mice (n = 
60; 15 mice per group). DFO plus gemcitabine reduced the 
tumor growth significantly (tested for S2-013 cell line only).
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therapy of solid tumor growth. Treatment with gemcitab-
ine in combination with ZnPP resulted in significantly
reduced tumor weights in tumors with high native HO-1
(PANC-1) in comparison to the only gemcitabine treated
control group. Inhibition of heme oxygenase-1 activity by
zinc protoporphyrin IX reduced tumor growth of LL/2
lung cancer in C57BL mice [30]. ZnPP probably interrupts
the direct proliferative effects of HO-1 on the cell cycle
[16]. In cultured cells (HA-1), ZnPP incubation increased
apoptosis by enhancing expression of p53 protein by the
Egr-1 protein, an antiproliferative signaling molecule in
tumor cells transactivating the promoter for the p53 gene
[31,32]. Typically, antioxidative enzymes like glutathione
peroxidase, catalase or superoxide dismutase are down-
regulated in tumor cells [33-35]. Thus, the HO-1 system,
whose activity is inhibited by ZnPP [7,19-21], may play a
major role in the defense against oxidative stress gener-
ated by chemotherapeutic agents in these cells. In contrast
to these findings, induction of HO-1 tended to increase
tumor growth in vivo and  in vitro in tumors with low
native HO-1 expression and impaired susceptibility to
chemotherapy.
These in vivo results support the suggested potential ther-
apeutic role of HO-1 inhibition in PaCa. Therefore, we
investigated whether anticancerous effects of HO-1 were
mediated by the heme degradation products bilirubin,
CO and iron.
Biliverdin showed protective effects against gemcitabine
on cell proliferation in all cell lines. In vivo (S2-013) the
administration of bilirubin in combination with gemcit-
abine tended to increase tumor growth (data not shown).
Bilirubin is a potent antioxidant that scavenges free radi-
cals [36-38]. The PaCa cells seem to utilize this antioxi-
dant produced by HO-1 to circumvent oxidative stress
generated by the chemotherapeutic agent.
Carbon monoxide (CO) did not show influence on cell
proliferation during gemcitabine treatment in vitro. CO, a
signal molecule triggering a series of signal transductions,
has nonetheless been shown to provide protection of cells
against injury of various kinds [9] both in vitro and in vivo
due to its antiapoptotic and anti-inflammatory activities.
CO inhibited TNFα-induced apoptosis in cultured fibrob-
lasts [39], provided protection against hyperoxic lung
injury in rats [40] and suppressed the rejection of mouse-
to-rat cardiac transplants [41]. Inhibition of HO-1
reversed the inhibitory effect of IL-10 on TNFα produc-
tion[42] Therefore, inhibition of HO-1 in tumor tissues
may increase TNFα production, hence increasing the
inflammatory response of the host. In our experiments
CO seems not to play a central role in PaCa growth. How-
ever, the observed tendency of increased proliferation
under CO treatment could justify further investigations.
Administration of ferrous histidinate had proliferative
effects in vitro. This is not surprising as iron containing
proteins catalyze key reactions involving energy metabo-
lism, respiration and DNA synthesis [43]. Iron is essential
for cellular growth and division, especially for rapidly pro-
liferating cancer cells. We showed that iron chelators can
target this altered iron metabolism of cancer cells [43]. In
the present study DFO had significant and profound anti-
proliferative effects on tumor cell growth in all cell lines.
In combination with gemcitabine DFO boosted signifi-
cantly the anti-proliferative effects of gemcitabine in
tumor cells. Also, tumors from S2-013 cancer cells treated
with a combination of gemcitabine with DFO had signif-
icantly decreased tumor weights compared to gemcitabine
treated mice. DFO already showed anti-tumoral effects on
other tumors in vitro as well as in limited clinical trials
[44]. DFO showed antileukemic effects on human mye-
loid leukemia cell lines [45]. It also led to growth inhibi-
tion in neuroblastoma cells [46] and showed anitumor
activity in neuroblastoma patients [47].
Conclusion
Our results showed that the inhibition of HO-1 in tumors
related to reduced tumor growth and increased respon-
siveness of PaCa to chemotherapy in vivo. Our study fur-
ther demonstrated that the anti-inflammatory and
antiapoptotic activities of HO-1, providing resistance of
PaCa cells to cellular stress from host immunity or anti-
cancer therapies, were at least partially exerted by its
metabolite biliverdin. Furthermore, the production of
iron seems to promote tumor growth. Based on this find-
ing, implementation of iron chelators displayed signifi-
cant antitumoral effects. Depletion of iron increased
susceptibility to chemotherapy in vivo and in vitro. There-
fore, HO-1 inhibition or direct interference with its
metabolites may evolve as new tactics in anticancer treat-
ment of PaCa.
Methods
Reagents
Gemcitabine (Lilly, Fegersheim, France) was dissolved in
PBS and diluted in 0.9% NaCl to a stock concentration of
24 mg/ml and stored at 4°C until use. Cobalt protopor-
phyrin (CoPP), zinc protoporphyrin (ZnPP) and biliver-
din hydrochloride (Frontier Scientific Inc., Logan, UT,
USA) were dissolved in 100 mM NaOH, subsequently
adjusted to a pH of 7.4 with 1 M HCl, and diluted in 0.9%
NaCl. The stock solutions of CoPP, ZnPP (1 mg/mL) and
biliverdin (10 mM) were aliquoted and stored at -80°C
until used. Desferrioxamine (DFO) mesylate (Sigma
Aldrich GmbH, Deisenhofen, Germany) was dissolved in
aqua ad injectabilia to a stock concentration of 0.5 g/mL
and diluted with 0.9% NaCl. All reagents were protected
from light exposure. Fe(II)-histidinate solution was
freshly prepared in PBS containing FeSO4 (10 mM) and L-Molecular Cancer 2009, 8:37 http://www.molecular-cancer.com/content/8/1/37
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histidine (100 mM) (Sigma Aldrich GmbH, Deisenhofen,
Germany).
Cell culture
The common human PaCa cell lines PANC-1 with ductal
cell origin and S2-013, derived from a metastatic liver
tumor of human pancreatic carcinoma, were cultured
using standard cell culture techniques, conditions and
media, supplemented with 10% fetal calf serum albumin
(PAN Biotech GmbH, Aidenbach, Germany), 100 U/mL
penicillin and 100 μg/mL streptomycin (Invitrogen, Karl-
sruhe, Germany), as previously described [48].
PANC-1 were obtained from American Type Cell Collec-
tion (Manassas, Virginia, USA), S2-013 cells were pro-
vided by Dr. M.A. Hollingsworth (Eppley Cancer Institute,
Omaha, NE, USA). Cells were incubated for at least 72
hours before each experiment and harvested with trypsin/
EDTA (0.05% Trypsin, 53 mM EDTA) (Invitrogen, Karl-
sruhe, Germany). S2-013 tumor cells were harvested at
90% confluency as previously described [22].
Real-time Light Cyclers QRT-PCR
All reagents and equipment for mRNA/cDNA preparation
were purchased from Roche Applied Science Diagnostics
(Mannheim, Germany). mRNA extractions from cells
were prepared by automated isolation using the MagNA
Pure® LC instrument and isolation kits I, cDNA was pre-
pared using the first strand cDNA synthesis kit according
to the manufacturer's instructions. Real-time PCR was per-
formed with the LightCycler® FastStart DNA SYBR Green
kit. All primers were obtained from Search-LC (Heidel-
berg, Germany). The calculated number of specific tran-
scripts was normalized to the housekeeping genes
cyclophilin B and hypoxanthine guanine phosphoribosyl-
transferase, and expressed as number of copies per ml of
input cDNA.
Immunoblotting
Cell lysates were prepared and sodium dodecyl sulfide-
polyacrylamide gel electrophoresis techniques were used
to separate proteins exactly as previously described [49].
The membranes were probed with primary anti-HO-1
mouse monoclonal antibody (BD Biosciences Transduc-
tion Laboratories, Lexington, KY, USA). Secondary perox-
idase-conjugated affinity purified goat anti-mouse
antibody (Jackson ImmunoResearch Laboratories, Inc.,
West Grove, Pennsylvania, USA) was used for detection,
as previously described [49]. Equal gel loading was con-
firmed by analyses with glyceraldehyde-3-phosphate
dehydrogenase antibody (Santa Cruz Biotechnology, Inc.,
Santa Cruz, California).
In vivo studies
Six- to eight-week-old female athymic nude (NU/NU)
mice (n = 135), each weighing at least 20 g, were pur-
chased from Charles River Laboratories, Inc. (Wilming-
ton, Massachusetts, USA). Mice were utilized in
accordance with the principles laid down in the European
Community's Council Directives and approved by the
local administration (reference 35-9185.81/G-138/04).
Animals were controlled on a daily basis and checked for
distress symptoms, as previously described [49].
Orthotopic Tumor Implantation
Mice were narcotized intraperitoneally with 0.05 ml of a
mixture of 0.4 ml of S-ketamine hydrochloride (Ketanest
S®, 25 mg/ml; Pfizer, Karlsruhe, Germany), 0.1 ml of xyla-
zine hydrochloride (Rompun®  2%; Bayer HealthCare,
Leverkusen, Germany), and 0.5 ml of NaCl. Orthotopic
tumor cell implantation was performed as described else-
where [22]. In brief, under sterile conditions, mice were
fixed in supine position and the abdomen was disinfected
with alcohol swabs. Following a 0.5 cm midline incision
and exposure of the situs the stomach was retracted to
expose the pancreas. Tumor cells (5 × 105 cells in 10 μl of
DMEM) were injected into the duodenal lobe using a
monoject 200 27-gauge × 1/2 in. polypropylene hub
hypodermic needle (Kendall, Mansfield, Massachusetts,
USA) and a 50 μl gastight glass syringe (Hamilton Com-
pany, Reno, Nevada, USA). The successful injection was
confirmed under a stereo microscope. After gentle reposi-
tion of the stomach into the peritoneal cavity, the incision
was sutured in two layers with vicryl-coated rapide sutures
4-0 (Ethicon, Inc., Somerville, New Jersey, USA). Mice
were closely monitored until awakened from narcosis and
afterwards transferred back to standardized animal care.
Treatment
One day after surgical orthotopic tumor cell implantation,
mice were randomized into the indicated groups. In both
cell lines, S2-013 and PANC-1, there were at least four
groups: control (group I), gemcitabine (group II), gemcit-
abine in combination with ZnPP (group II) and gemcitab-
Table 1: Different categories of treatment for PANC-1 cell line
# Group n Treatment
I control 15 -
II gemcitabine* 15 gemcitabine
III gemcitabine/CoPP† 15 gemcitabine/CoPP
IV gemcitabine/ZnPP† 15 gemcitabine/ZnPP
* Gemcitabine (5 doses, 60 mg/kg per dose) on days 11, 14, 17, 20 
and 23.
† CoPP or ZnPP (5 mg/kg per dose) every alternative day from day 9 
to day 23.Molecular Cancer 2009, 8:37 http://www.molecular-cancer.com/content/8/1/37
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ine in combination with CoPP (group IV) (Table 1, Table
2).
In both cell lines, group I (control) received intraperito-
neal injections of the vehicle only. Group II (gemcitabine)
received intraperitoneal injections of gemcitabine (60
mg/kg per dose) on days 7, 10, 13, and 17 (S2-013, total
of 4 doses) and on days 11, 14, 17, 20 and 23 (PANC-1,
total of 5 doses) after tumor injection. Group III (gemcit-
abine with ZnPP) was additionally administered ZnPP (5
mg/kg per dose) every alternative day starting two days
prior to the first dose and finishing after last dose of gem-
citabine. Group IV (gemcitabine with CoPP) received
injections of CoPP (5 mg/kg per dose) in the same regi-
men as group III (Table 1, Table 2).
For the S2-013 cell line treatment combining gemcitabine
with desferrioxamine (DFO) (group V) was tested: Mice of
group IV (gemcitabine with DFO) were implanted
osmotic pumps (Alzet©  Osmotic Pump 1002; Alzet
Osmotic Pumps, Cupertino, California, USA) for DFO
delivery (250 mg/kg per day for two weeks) subcutane-
ously on day 5 after tumor implantation (not tested for
PANC-1 cell line).
Technical read-out of pancreatic tumors
Fifteen mice were assigned to each group and treated for 4
weeks in case of S2-013 and 8 weeks in case of PANC-1
cancer cell treatment, at which time the experiment was
terminated. Mice were euthanized and staging and imag-
ing of implanted and newly formed tumor masses were
performed as previously described [22]. Peritoneal and
pancreatic tumors were weighed, measured and tumor
volume (data not shown) was calculated as previously
described [22]. Tissues were fixed in 4% formaldehyde
and then transferred to 70% ethanol. Afterwards tissues
were paraffin-embedded according to histology standard
protocols.
Cell proliferation assay
The 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazo-
lium bromide (MTT) (Sigma Aldrich, Deisendorf, Ger-
many) cell proliferation assay was done to assess cell
proliferation and to evaluate the effect of HO-1 and its
metabolites on cell proliferation rate. Cells were seeded in
96-well culture plates at densities of 3,000 cells per well
for S2-013 and 4,000 cells per well for PANC-1. Following
incubation overnight, metabolites and gemcitabine were
added at indicated concentrations and incubated for 72 h,
before 20 μl MTT (5 mg/ml in PBS; pH 7.4) were added to
each well for 4 h. Formazan products were solubilized
with acidic isopropanol, and the optical density was
measured at 570 nm. The absorbance was corrected for
blank readings. All experiments were carried out in sextu-
plicate and were repeated at least three times.
Statistical analysis
The data are presented as mean ± standard deviation (SD).
P < 0.05 was considered statistically significant. The
Mann-Whitney test was employed to compare differences
between two independent groups. Multiple comparisons
of tumor weights were tested using Kruskal-Wallis
ANOVA on ranks as a nonparametric test. Dunn's post test
was used as a post-hoc test. Statistical analysis of data was
performed and graphs were created using the GraphPad
Prism Software 5.01 (GraphPad Software, Inc., San Diego,
CA, USA).
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
PN performed the in vitro and in vivo studies and drafted
the manuscript. BMK participated in drafting the manu-
script and coordination of the study. RH and RN helped
to establish the in vivo model. TM and TR participated in
performing the in vivo studies. SCM and HF participated in
coordination of the study. POB designed the study and
coordinated and helped to draft the paper. All authors
read and approved the final manuscript.
References
1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ: Cancer statis-
tics, 2007.  CA Cancer J Clin 2007, 57:43-66.
2. Ghaneh P, Slavin J, Sutton R, Hartley M, Neoptolemos JP: Adjuvant
therapy in pancreatic cancer.  World J Gastroenterol 2001,
7:482-489.
3. Otterbein LE, Choi AM: Heme oxygenase: colors of defense
against cellular stress.  Am J Physiol Lung Cell Mol Physiol 2000,
279:L1029-1037.
4. Maines MD: The heme oxygenase system: a regulator of sec-
ond messenger gases.  Annu Rev Pharmacol Toxicol 1997,
37:517-554.
5. Schacter BA: Heme catabolism by heme oxygenase: physiol-
ogy, regulation, and mechanism of action.  Semin Hematol 1988,
25:349-369.
Table 2: Different categories of treatment for S2-013 cell line
# Group n Treatment
I control 15 -
II gemcitabine* 15 gemcitabine
III gemcitabine/CoPP† 15 gemcitabine/CoPP
V gemcitabine/DFO‡ 15 gemcitabine/DFO
IV gemcitabine/ZnPP† 15 gemcitabine/ZnPP
* Gemcitabine (4 doses, 60 mg/kg per dose) on days 7, 10, 13 and 17.
† CoPP, ZnPP (5 mg/kg per dose) or biliverdin (50 μmol/kg per dose) 
every alternative day from day 5 to day 17.
‡ DFO administration via an intraperitoneal osmotic pump (250 mg/kg 
per day for two weeks) from day 7 onwards.Molecular Cancer 2009, 8:37 http://www.molecular-cancer.com/content/8/1/37
Page 9 of 10
(page number not for citation purposes)
6. Otterbein LE, Bach FH, Alam J, Soares M, Tao Lu H, Wysk M, Davis
RJ, Flavell RA, Choi AM: Carbon monoxide has anti-inflamma-
tory effects involving the mitogen-activated protein kinase
pathway.  Nat Med 2000, 6:422-428.
7. Berberat PO, Katori M, Kaczmarek E, Anselmo D, Lassman C, Ke B,
Shen X, Busuttil RW, Yamashita K, Csizmadia E, et al.: Heavy chain
ferritin acts as an antiapoptotic gene that protects livers
from ischemia reperfusion injury.  Faseb J 2003, 17:1724-1726.
8. Pae HO, Oh GS, Choi BM, Chae SC, Kim YM, Chung KR, Chung HT:
Carbon monoxide produced by heme oxygenase-1 sup-
presses T cell proliferation via inhibition of IL-2 production.
J Immunol 2004, 172:4744-4751.
9. Otterbein LE, Soares MP, Yamashita K, Bach FH: Heme oxygenase-
1: unleashing the protective properties of heme.  Trends Immu-
nol 2003, 24:449-455.
10. Sunamura M, Duda DG, Ghattas MH, Lozonschi L, Motoi F, Yamauchi
J, Matsuno S, Shibahara S, Abraham NG: Heme oxygenase-1 accel-
erates tumor angiogenesis of human pancreatic cancer.  Ang-
iogenesis 2003, 6:15-24.
11. Elbirt KK, Whitmarsh AJ, Davis RJ, Bonkovsky HL: Mechanism of
sodium arsenite-mediated induction of heme oxygenase-1 in
hepatoma cells. Role of mitogen-activated protein kinases.  J
Biol Chem 1998, 273:8922-8931.
12. Tanaka S, Akaike T, Fang J, Beppu T, Ogawa M, Tamura F, Miyamoto
Y, Maeda H: Antiapoptotic effect of haem oxygenase-1
induced by nitric oxide in experimental solid tumour.  Br J
Cancer 2003, 88:902-909.
13. Goodman AI, Choudhury M, da Silva JL, Schwartzman ML, Abraham
NG: Overexpression of the heme oxygenase gene in renal
cell carcinoma.  Proc Soc Exp Biol Med 1997, 214:54-61.
14. Maines MD, Abrahamsson PA: Expression of heme oxygenase-1
(HSP32) in human prostate: normal, hyperplastic, and
tumor tissue distribution.  Urology 1996, 47:727-733.
15. Schacter BA, Kurz P: Alterations in microsomal drug metabo-
lism and heme oxygenase activity in isolated hepatic paren-
chymal and sinusoidal cells in Murphy-Sturm
lymphosarcoma-bearing rats.  Clin Invest Med 1986, 9:150-155.
16. Berberat PO, Dambrauskas Z, Gulbinas A, Giese T, Giese N, Kunzli
B, Autschbach F, Meuer S, Buchler MW, Friess H: Inhibition of
heme oxygenase-1 increases responsiveness of pancreatic
cancer cells to anticancer treatment.  Clin Cancer Res 2005,
11:3790-3798.
17. Christova TY, Gorneva GA, Taxirov SI, Duridanova DB, Setchenska
MS:  Effect of cisplatin and cobalt chloride on antioxidant
enzymes in the livers of Lewis lung carcinoma-bearing mice:
protective role of heme oxygenase.  Toxicol Lett 2003,
138:235-242.
18. Doi K, Akaike T, Fujii S, Tanaka S, Ikebe N, Beppu T, Shibahara S,
Ogawa M, Maeda H: Induction of haem oxygenase-1 nitric
oxide and ischaemia in experimental solid tumours and
implications for tumour growth.  Br J Cancer 1999,
80:1945-1954.
19. Fang J, Sawa T, Akaike T, Akuta T, Sahoo SK, Khaled G, Hamada A,
Maeda H: In vivo antitumor activity of pegylated zinc pro-
toporphyrin: targeted inhibition of heme oxygenase in solid
tumor.  Cancer Res 2003, 63:3567-3574.
20. Hancock WW, Buelow R, Sayegh MH, Turka LA: Antibody-
induced transplant arteriosclerosis is prevented by graft
expression of anti-oxidant and anti-apoptotic genes.  Nat Med
1998, 4:1392-1396.
21. Willis D, Moore AR, Frederick R, Willoughby DA: Heme oxygen-
ase: a novel target for the modulation of the inflammatory
response.  Nat Med 1996, 2:87-90.
22. Hennig R, Ventura J, Segersvard R ,  W a r d  E ,  D i n g  X Z ,  R a o  S M ,
Jovanovic BD, Iwamura T, Talamonti MS, Bell RH Jr, Adrian TE:
LY293111 improves efficacy of gemcitabine therapy on pan-
creatic cancer in a fluorescent orthotopic model in athymic
mice.  Neoplasia 2005, 7:417-425.
23. Durante W: Heme oxygenase-1 in growth control and its clin-
ical application to vascular disease.  J Cell Physiol 2003,
195:373-382.
24. Katori M, Buelow R, Ke B, Ma J, Coito AJ, Iyer S, Southard D, Busuttil
RW, Kupiec-Weglinski JW: Heme oxygenase-1 overexpression
protects rat hearts from cold ischemia/reperfusion injury via
an antiapoptotic pathway.  Transplantation 2002, 73:287-292.
25. Ryter SW, Otterbein LE: Carbon monoxide in biology and med-
icine.  Bioessays 2004, 26:270-280.
26. Yet SF, Tian R, Layne MD, Wang ZY, Maemura K, Solovyeva M, Ith B,
Melo LG, Zhang L, Ingwall JS, et al.: Cardiac-specific expression of
heme oxygenase-1 protects against ischemia and reper-
fusion injury in transgenic mice.  Circ Res 2001, 89:168-173.
27. Otterbein LE, Kolls JK, Mantell LL, Cook JL, Alam J, Choi AM: Exog-
enous administration of heme oxygenase-1 by gene transfer
provides protection against hyperoxia-induced lung injury.  J
Clin Invest 1999, 103:1047-1054.
28. Torisu-Itakura H, Furue M, Kuwano M, Ono M: Co-expression of
thymidine phosphorylase and heme oxygenase-1 in macro-
phages in human malignant vertical growth melanomas.  Jpn
J Cancer Res 2000, 91:906-910.
29. Nishie A, Ono M, Shono T, Fukushi J, Otsubo M, Onoue H, Ito Y, Ina-
mura T, Ikezaki K, Fukui M, et al.: Macrophage infiltration and
heme oxygenase-1 expression correlate with angiogenesis in
human gliomas.  Clin Cancer Res 1999, 5:1107-1113.
30. Hirai K, Sasahira T, Ohmori H, Fujii K, Kuniyasu H: Inhibition of
heme oxygenase-1 by zinc protoporphyrin IX reduces tumor
growth of LL/2 lung cancer in C57BL mice.  Int J Cancer 2007,
120:500-505.
31. Nair P, Muthukkumar S, Sells SF, Han SS, Sukhatme VP, Rangnekar
VM: Early growth response-1-dependent apoptosis is medi-
ated by p53.  J Biol Chem 1997, 272:20131-20138.
32. Yang G, Nguyen X, Ou J, Rekulapelli P, Stevenson DK, Dennery PA:
Unique effects of zinc protoporphyrin on HO-1 induction
and apoptosis.  Blood 2001, 97:1306-1313.
33. Sato K, Ito K, Kohara H, Yamaguchi Y, Adachi K, Endo H: Negative
regulation of catalase gene expression in hepatoma cells.  Mol
Cell Biol 1992, 12:2525-2533.
34. Hasegawa Y, Takano T, Miyauchi A, Matsuzuka F, Yoshida H, Kuma K,
Amino N: Decreased expression of glutathione peroxidase
mRNA in thyroid anaplastic carcinoma.  Cancer Lett 2002,
182:69-74.
35. Yamanaka N, Deamer D: Superoxide dismutase activity in WI-
38 cell cultures: effects of age, trypsinization and SV-40
transformation.  Physiol Chem Phys 1974, 6:95-106.
36. Farrera JA, Jauma A, Ribo JM, Peire MA, Parellada PP, Roques-Choua
S, Bienvenue E, Seta P: The antioxidant role of bile pigments
evaluated by chemical tests.  Bioorg Med Chem 1994, 2:181-185.
37. Minetti M, Mallozzi C, Di Stasi AM, Pietraforte D: Bilirubin is an
effective antioxidant of peroxynitrite-mediated protein oxi-
dation in human blood plasma.  Arch Biochem Biophys 1998,
352:165-174.
38. Dore S, Takahashi M, Ferris CD, Zakhary R, Hester LD, Guastella D,
Snyder SH: Bilirubin, formed by activation of heme oxygen-
ase-2, protects neurons against oxidative stress injury.  Proc
Natl Acad Sci USA 1999, 96:2445-2450.
39. Petrache I, Otterbein LE, Alam J, Wiegand GW, Choi AM: Heme
oxygenase-1 inhibits TNF-alpha-induced apoptosis in cul-
tured fibroblasts.  Am J Physiol Lung Cell Mol Physiol 2000,
278:L312-319.
40. Otterbein LE, Mantell LL, Choi AM: Carbon monoxide provides
protection against hyperoxic lung injury.  Am J Physiol 1999,
276:L688-694.
41. Sato K, Balla J, Otterbein L, Smith RN, Brouard S, Lin Y, Csizmadia E,
Sevigny J, Robson SC, Vercellotti G, et al.: Carbon monoxide gen-
erated by heme oxygenase-1 suppresses the rejection of
mouse-to-rat cardiac transplants.  J Immunol 2001,
166:4185-4194.
42. Lee TS, Chau LY: Heme oxygenase-1 mediates the anti-inflam-
matory effect of interleukin-10 in mice.  Nat Med 2002,
8:240-246.
43. Richardson DR: Molecular mechanisms of iron uptake by cells
and the use of iron chelators for the treatment of cancer.
Curr Med Chem 2005, 12:2711-2729.
44. Darnell G, Richardson DR: The potential of iron chelators of the
pyridoxal isonicotinoyl hydrazone class as effective antipro-
liferative agents III: the effect of the ligands on molecular
targets involved in proliferation.  Blood 1999, 94:781-792.
45. Becton DL, Roberts B: Antileukemic effects of deferoxamine
on human myeloid leukemia cell lines.  Cancer Res 1989,
49:4809-4812.
46. Brodie C, Siriwardana G, Lucas J, Schleicher R, Terada N, Szepesi A,
Gelfand E, Seligman P: Neuroblastoma sensitivity to growthPublish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Molecular Cancer 2009, 8:37 http://www.molecular-cancer.com/content/8/1/37
Page 10 of 10
(page number not for citation purposes)
inhibition by deferrioxamine: evidence for a block in G1
phase of the cell cycle.  Cancer Res 1993, 53:3968-3975.
47. Donfrancesco A, Deb G, Dominici C, Pileggi D, Castello MA, Helson
L: Effects of a single course of deferoxamine in neuroblast-
oma patients.  Cancer Res 1990, 50:4929-4930.
48. Guo J, Kleeff J, Li J, Ding J, Hammer J, Zhao Y, Giese T, Korc M, Buch-
ler MW, Friess H: Expression and functional significance of
CDC25B in human pancreatic ductal adenocarcinoma.  Onco-
gene 2004, 23:71-81.
49. Kunzli BM, Nuhn P, Enjyoji K, Banz Y, Smith RN, Csizmadia E, Schup-
pan D, Berberat PO, Friess H, Robson SC: Disordered Pancreatic
Inflammatory Responses and Inhibition of Fibrosis in CD39-
Null Mice.  Gastroenterology 2008, 134(1):292-305.